Which of the following is NOT listed as a common adverse effect of alirocumab?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which of the following is NOT listed as a common adverse effect of alirocumab?

A key idea here is understanding how labeling classifies adverse effects by how often they occur. In alirocumab labeling, common adverse events are those seen with a notable frequency in trials—typically around or above 1% of patients. The events that show up most frequently with this drug include urinary tract infections, upper respiratory tract infections, and influenza. Dizziness, while it can occur, is not listed among the common adverse effects in the product information, so it isn’t considered a common adverse effect. When reviewing these lists, always check the actual frequency data in the labeling, since some symptoms may occur infrequently and would be labeled as uncommon rather than common.

A key idea here is understanding how labeling classifies adverse effects by how often they occur. In alirocumab labeling, common adverse events are those seen with a notable frequency in trials—typically around or above 1% of patients. The events that show up most frequently with this drug include urinary tract infections, upper respiratory tract infections, and influenza. Dizziness, while it can occur, is not listed among the common adverse effects in the product information, so it isn’t considered a common adverse effect. When reviewing these lists, always check the actual frequency data in the labeling, since some symptoms may occur infrequently and would be labeled as uncommon rather than common.

More practice questions